Non-immunotherapy application of LNP-mRNA: Maximizing efficacy and safety

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · see citing works

Toll-like receptor signalling

Akira, S., & Takeda, K. (2004) · Nature reviews. Immunology · doi:10.1038/nri1391 · Cited by 8,312 · see citing works

Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death

Shi, J., Zhao, Y., Wang, K., Shi, X., Wang, Y., Huang, H., Zhuang, Y., Cai, T., Wang, F., & Shao, F. (2015) · Nature · doi:10.1038/nature15514 · Cited by 6,659 · see citing works

Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3

Alexopoulou, L., Holt, A. C., Medzhitov, R., & Flavell, R. A. (2001) · Nature · doi:10.1038/35099560 · Cited by 6,129 · see citing works

mRNA vaccines — a new era in vaccinology

Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667 · see citing works

PEGylation as a strategy for improving nanoparticle-based drug and gene delivery

Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523 · see citing works

Direct Gene Transfer into Mouse Muscle in Vivo

Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173 · cited 1× · see citing works

Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8

Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947 · see citing works

Cytokine storm

Fajgenbaum, D. C., & June, C. H. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2026131 · Cited by 3,196 · see citing works

Knocking down barriers: advances in siRNA delivery

Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115 · see citing works

Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA

Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728 · see citing works

mRNA-based therapeutics--developing a new class of drugs

Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474 · see citing works

eIF4 Initiation Factors: Effectors of mRNA Recruitment to Ribosomes and Regulators of Translation

Gingras, A., Raught, B., & Sonenberg, N. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.913 · Cited by 2,103 · see citing works

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977 · see citing works

Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability

Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930 · see citing works

Innate immune recognition of viral infection

Kawai, T., & Akira, S. (2006) · Nature Immunology · doi:10.1038/ni1303 · Cited by 1,899 · see citing works

Rational design of cationic lipids for siRNA delivery

Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822 · cited 1× · see citing works

Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy

Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,771 · see citing works

RIG-I-like receptors: their regulation and roles in RNA sensing

Rehwinkel, J., & Gack, M. U. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-0288-3 · Cited by 1,703 · see citing works

Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies

Mitragotri, S., Burke, P. A., & Langer, R. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4363 · Cited by 1,702 · see citing works

SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness

Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615 · see citing works

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523 · see citing works

Codon bias and heterologous protein expression

Gustafsson, C., Govindarajan, S., & Minshull, J. (2004) · Trends in Biotechnology · doi:10.1016/j.tibtech.2004.04.006 · Cited by 1,330 · see citing works

RNA Editing by Adenosine Deaminases That Act on RNA

Bass, B. (2002) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.71.110601.135501 · Cited by 1,272 · see citing works

Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms

Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261 · see citing works

Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery

Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127 · see citing works

Translational control by 5′-untranslated regions of eukaryotic mRNAs

Hinnebusch, A. G., Ivanov, I. P., & Sonenberg, N. (2016) · Science · doi:10.1126/science.aad9868 · Cited by 1,079 · see citing works

A-to-I editing of coding and non-coding RNAs by ADARs

Nishikura, K. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2015.4 · Cited by 1,024 · see citing works

Circularization of mRNA by Eukaryotic Translation Initiation Factors

Wells, S. E., Hillner, P. E., Vale, R. D., & Sachs, A. B. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80122-7 · Cited by 968 · see citing works

RNA editing by ADAR1 prevents MDA5 sensing of endogenous dsRNA as nonself

Liddicoat, B., Piskol, R., Chalk, A. M., Ramaswami, G., Higuchi, M., Hartner, J. C., Li, J. B., Seeburg, P. H., & Walkley, C. R. (2015) · Science · doi:10.1126/science.aac7049 · Cited by 955 · see citing works

Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines

Hassett, K. J., Benenato, K. E., Jacquinet, E., Lee, A., Woods, A., Yuzhakov, O., Himansu, S., Deterling, J., Geilich, B. M., Ketova, T., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.01.013 · Cited by 927 · see citing works

BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans

Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914 · see citing works

Modified mRNA vaccines protect against zika virus infection

Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909 · see citing works

Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA

Karikó, K., Muramatsu, H., Ludwig, J., & Weissman, D. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr695 · Cited by 898 · see citing works

mRNA capping: biological functions and applications

Ramanathan, A., Robb, G. B., & Chan, S. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw551 · Cited by 892 · see citing works

Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination

Pardi, N., Hogan, M. J., Pelc, R. S., Muramatsu, H., Andersen, H., DeMaso, C. R., Dowd, K. A., Sutherland, L. L., Scearce, R. M., Parks, R., et al. (2017) · Nature · doi:10.1038/nature21428 · Cited by 884 · see citing works

The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency.

Gallie, D. R. (1991) · Genes & Development · doi:10.1101/gad.5.11.2108 · Cited by 868 · see citing works

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 845 · see citing works

A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates

Sabnis, S., Kumarasinghe, E. S., Salerno, T., Mihai, C., Ketova, T., Senn, J. J., Lynn, A., Bulychev, A., McFadyen, I., Chan, J., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.03.010 · Cited by 820 · see citing works

Ribose 2'-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5

Züst, R., Cervantes-Barragan, L., Habjan, M., Maier, R., Neuman, B. W., Ziebuhr, J., Szretter, K. J., Baker, S. C., Barchet, W., Diamond, M. S., et al. (2011) · Nature Immunology · doi:10.1038/ni.1979 · Cited by 811 · see citing works

Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs

Kauffman, K. J., Dorkin, J. R., Yang, J. H., Heartlein, M. W., DeRosa, F., Mir, F. F., Fenton, O. S., & Anderson, D. G. (2015) · Nano Letters · doi:10.1021/acs.nanolett.5b02497 · Cited by 785 · see citing works

Expression of therapeutic proteins after delivery of chemically modified mRNA in mice

Kormann, M. S. D., Hasenpusch, G., Aneja, M. K., Nica, G., Flemmer, A. W., Herber-Jonat, S., Huppmann, M., Mays, L. E., Illenyi, M., Schams, A., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1733 · Cited by 733 · see citing works

The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage

Abu Lila, A. S., Kiwada, H., & Ishida, T. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.07.026 · Cited by 721 · see citing works

N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice

Andries, O., Mc Cafferty, S., De Smedt, S. C., Weiss, R., Sanders, N. N., & Kitada, T. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.051 · Cited by 701 · see citing works

Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals

Kozma, G. T., Shimizu, T., Ishida, T., & Szebeni, J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.024 · Cited by 696 · see citing works

Viral Encounters with 2′,5′-Oligoadenylate Synthetase and RNase L during the Interferon Antiviral Response

Silverman, R. H. (2007) · Journal of Virology · doi:10.1128/jvi.01471-07 · Cited by 677 · see citing works

Poly(A)-tail profiling reveals an embryonic switch in translational control

Subtelny, A. O., Eichhorn, S. W., Chen, G. R., Sive, H., & Bartel, D. P. (2014) · Nature · doi:10.1038/nature13007 · Cited by 664 · see citing works

Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses

Bahl, K., Senn, J. J., Yuzhakov, O., Bulychev, A., Brito, L. A., Hassett, K. J., Laska, M. E., Smith, M., Almarsson, Ö., Thompson, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.035 · Cited by 642 · see citing works

Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics

Maier, M. A., Jayaraman, M., Matsuda, S., Liu, J., Barros, S., Querbes, W., Tam, Y. K., Ansell, S. M., Kumar, V., Qin, J., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.124 · Cited by 625 · see citing works

Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells

Holtkamp, S., Kreiter, S., Selmi, A., Simon, P., Koslowski, M., Huber, C., Türeci, O., & Sahin, U. (2006) · Blood · doi:10.1182/blood-2006-04-015024 · Cited by 625 · see citing works

Accelerated Blood Clearance and Altered Biodistribution of Repeated Injections of Sterically Stabilized Liposomes

Dams, E. T. M., Laverman, P., Oyen, W. J. G., Storm, G., Scherphof, G. L., van der Meer, J. W. M., Corstens, F. H. M., & Boerman, O. C. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35391-1 · Cited by 606 · see citing works

Crystal Structure of Human Toll-Like Receptor 3 (TLR3) Ectodomain

Choe, J., Kelker, M. S., & Wilson, I. A. (2005) · Science · doi:10.1126/science.1115253 · Cited by 603 · see citing works

Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA

Patel, S., Ashwanikumar, N., Robinson, E., Xia, Y., Mihai, C., Griffith, J. P., Hou, S., Esposito, A. A., Ketova, T., Welsher, K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14527-2 · Cited by 601 · see citing works

Lipid nanoparticles for nucleic acid delivery: Current perspectives

Samaridou, E., Heyes, J. A., & Lutwyche, P. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.002 · Cited by 593 · see citing works

A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA

Baiersdörfer, M., Boros, G., Muramatsu, H., Mahiny, A., Vlatkovic, I., Sahin, U., & Karikó, K. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.02.018 · Cited by 569 · see citing works

Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5'-diphosphates

Goubau, D., Schlee, M., Deddouche, S., Pruijssers, A. J., Zillinger, T., Goldeck, M., Schuberth, C., Van der Veen, A. G., Fujimura, T., Rehwinkel, J., et al. (2014) · Nature · doi:10.1038/nature13590 · Cited by 557 · see citing works

The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation

Kedmi, R., Ben-Arie, N., & Peer, D. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.05.027 · Cited by 546 · see citing works

Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines

Thi, T. T. H., Suys, E. J. A., Lee, J. S., Nguyen, D. H., Park, K. D., & Truong, N. P. (2021) · Vaccines · doi:10.3390/vaccines9040359 · Cited by 538 · see citing works

PEGylated liposomes: immunological responses

Sayed, M. M. E., Lila, A. S. A., Shimizu, T., Alaaeldin, E., Hussein, A. K., Sarhan, H. A., Szebeni, J., & Ishida, T. (2019) · Science and Technology of Advanced Materials · doi:10.1080/14686996.2019.1627174 · Cited by 536 · see citing works

Essential Role for the dsRNA-Dependent Protein Kinase PKR in Innate Immunity to Viral Infection

Balachandran, S., Roberts, P. C., Brown, L. E., Truong, H., Pattnaik, A. K., Archer, D. R., & Barber, G. N. (2000) · Immunity · doi:10.1016/s1074-7613(00)00014-5 · Cited by 527 · see citing works

Recent advances in mRNA vaccine technology

Pardi, N., Hogan, M. J., & Weissman, D. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.01.008 · Cited by 512 · see citing works

ADAR1 is essential for the maintenance of hematopoiesis and suppression of interferon signaling

Hartner, J. C., Walkley, C. R., Lü, J., & Orkin, S. H. (2008) · Nature Immunology · doi:10.1038/ni.1680 · Cited by 493 · see citing works

Self-amplifying RNA vaccines for infectious diseases

Bloom, K., van den Berg, F., & Arbuthnot, P. (2021) · Gene Therapy · doi:10.1038/s41434-020-00204-y · Cited by 487 · see citing works

Activation of MDA5 Requires Higher-Order RNA Structures Generated during Virus Infection

Pichlmair, A., Schulz, O., Tan, C.-P., Rehwinkel, J., Kato, H., Takeuchi, O., Akira, S., Way, M., Schiavo, G., & Sousa, C. R. E. (2009) · Journal of Virology · doi:10.1128/jvi.00770-09 · Cited by 469 · see citing works

Complement activation-related pseudoallergy: A stress reaction in blood triggered by nanomedicines and biologicals

Szebeni, J. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.06.038 · Cited by 457 · see citing works

TAIL-seq: Genome-wide Determination of Poly(A) Tail Length and 3′ End Modifications

Chang, H., Lim, J., Ha, M., & Kim, V. N. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.02.007 · Cited by 454 · see citing works

Human 5′ UTR design and variant effect prediction from a massively parallel translation assay

Sample, P. J., Wang, B., Reid, D. W., Presnyak, V., McFadyen, I. J., Morris, D. R., & Seelig, G. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0164-5 · Cited by 442 · see citing works

Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells

Maugeri, M., Nawaz, M., Papadimitriou, A., Angerfors, A., Camponeschi, A., Na, M., Hölttä, M., Skantze, P., Johansson, S., Sundqvist, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12275-6 · Cited by 428 · see citing works

Cytokines as biomarkers of nanoparticle immunotoxicity

Elsabahy, M., & Wooley, K. L. (2013) · Chemical Society Reviews · doi:10.1039/c3cs60064e · Cited by 408 · see citing works

5′-triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I

Schmidt, A., Schwerd, T., Hamm, W., Hellmuth, J. C., Cui, S., Wenzel, M., Hoffmann, F. S., Michallet, M.-C., Besch, R., Hopfner, K.-P., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900971106 · Cited by 398 · see citing works

Recent Advances in Understanding the Protein Corona of Nanoparticles and in the Formulation of “Stealthy” Nanomaterials

Rampado, R., Crotti, S., Caliceti, P., Pucciarelli, S., & Agostini, M. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00166 · Cited by 395 · see citing works

mRNA therapeutics in cancer immunotherapy

Beck, J. D., Reidenbach, D., Salomon, N., Sahin, U., Türeci, Ö., Vormehr, M., & Kranz, L. M. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01348-0 · Cited by 385 · see citing works

Deconvoluting Lipid Nanoparticle Structure for Messenger RNA Delivery

Eygeris, Y., Patel, S., Jozić, A., & Sahay, G. (2020) · Nano Letters · doi:10.1021/acs.nanolett.0c01386 · Cited by 382 · see citing works

Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3′ UTRs Identified by Cellular Library Screening

Orlandini von Niessen, A. G., Poleganov, M. A., Rechner, C., Plaschke, A., Kranz, L. M., Fesser, S., Diken, M., Löwer, M., Vallazza, B., Beissert, T., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.12.011 · Cited by 365 · see citing works

Cytokine Levels in the Serum of Healthy Subjects

Kleiner, G., Marcuzzi, A., Zanin, V., Monasta, L., & Zauli, G. (2013) · Mediators of Inflammation · doi:10.1155/2013/434010 · Cited by 358 · see citing works

Structural basis for m7G recognition and 2′-O-methyl discrimination in capped RNAs by the innate immune receptor RIG-I

Devarkar, S. C., Wang, C., Miller, M. T., Ramanathan, A., Jiang, F., Khan, A. G., Patel, S. S., & Marcotrigiano, J. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1515152113 · Cited by 357 · see citing works

Regulation of Macrophage Recognition through the Interplay of Nanoparticle Surface Functionality and Protein Corona

Saha, K., Rahimi, M., Yazdani, M., Kim, S. T., Moyano, D. F., Hou, S., Das, R., Mout, R., Rezaee, F., Mahmoudi, M., et al. (2016) · ACS Nano · doi:10.1021/acsnano.6b00053 · Cited by 356 · see citing works

Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge

Pardi, N., Secreto, A. J., Shan, X., Debonera, F., Glover, J., Yi, Y., Muramatsu, H., Ni, H., Mui, B. L., Tam, Y. K., et al. (2017) · Nature Communications · doi:10.1038/ncomms14630 · Cited by 352 · see citing works

Nucleic Acid Delivery: The Missing Pieces of the Puzzle?

Nguyen, J., & Szoka, F. C. (2012) · Accounts of Chemical Research · doi:10.1021/ar3000162 · Cited by 347 · see citing works

Effects of engineered nanoparticles on the innate immune system

Liu, Y., Hardie, J. M., Zhang, X., & Rotello, V. M. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.09.011 · Cited by 346 · see citing works

A critical analysis of codon optimization in human therapeutics

Mauro, V. P., & Chappell, S. A. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.09.003 · Cited by 343 · see citing works

"Cytokine Storm" in the Phase I Trial of Monoclonal Antibody TGN1412: Better Understanding the Causes to Improve PreClinical Testing of Immunotherapeutics

Stebbings, R., Findlay, L., Edwards, C., Eastwood, D., Bird, C., North, D., Mistry, Y., Dilger, P., Liefooghe, E., Cludts, I., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.5.3325 · Cited by 317 · see citing works

High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing

Sago, C. D., Lokugamage, M. P., Paunovska, K., Vanover, D. A., Monaco, C. M., Shah, N. N., Gamboa Castro, M., Anderson, S. E., Rudoltz, T. G., Lando, G. N., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1811276115 · Cited by 313 · see citing works

A Conserved Histidine in the RNA Sensor RIG-I Controls Immune Tolerance to N1-2′O-Methylated Self RNA

Schuberth-Wagner, C., Ludwig, J., Bruder, A. K., Herzner, A., Zillinger, T., Goldeck, M., Schmidt, T., Schmid-Burgk, J. L., Kerber, R., Wolter, S., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.06.015 · Cited by 311 · see citing works

Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes

Veiga, N., Goldsmith, M., Granot, Y., Rosenblum, D., Dammes, N., Kedmi, R., Ramishetti, S., & Peer, D. (2018) · Nature Communications · doi:10.1038/s41467-018-06936-1 · Cited by 308 · see citing works

Human NLRP1 is a sensor for double-stranded RNA

Bauernfried, S., Scherr, M. J., Pichlmair, A., Duderstadt, K. E., & Hornung, V. (2021) · Science · doi:10.1126/science.abd0811 · Cited by 304 · see citing works

Systemic delivery of factor IX messenger RNA for protein replacement therapy

Ramaswamy, S., Tonnu, N., Tachikawa, K., Limphong, P., Vega, J. B., Karmali, P. P., Chivukula, P., & Verma, I. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1619653114 · Cited by 301 · see citing works

The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer

Wisse, E., Jacobs, F., Topal, B., Frederik, P. M., & Geest, B. D. (2008) · Gene Therapy · doi:10.1038/gt.2008.60 · Cited by 290 · see citing works

Elimination of large tumors in mice by mRNA-encoded bispecific antibodies

Stadler, C. R., Bähr-Mahmud, H., Celik, L., Hebich, B., Roth, A. S., Roth, R. P., Karikó, K., Türeci, Ö., & Sahin, U. (2017) · Nature Medicine · doi:10.1038/nm.4356 · Cited by 290 · see citing works

An Update on Self-Amplifying mRNA Vaccine Development

Blakney, A. K., Ip, S., & Geall, A. J. (2021) · Vaccines · doi:10.3390/vaccines9020097 · Cited by 288 · see citing works

Antibodies against Polyethylene Glycol Produced in Animals by Immunization with Monomethoxy Polyethylene Glycol Modified Proteins

Richter, A. W., & Akerblom, E. B. (2009) · International Archives of Allergy and Applied Immunology · doi:10.1159/000233309 · Cited by 282 · see citing works

Nucleic acid agonists for Toll‐like receptor 7 are defined by the presence of uridine ribonucleotides

Diebold, S. S., Massacrier, C., Akira, S., Paturel, C., Morel, Y., & Sousa, C. R. E. (2006) · European Journal of Immunology · doi:10.1002/eji.200636617 · Cited by 281 · see citing works

Hypersensitivity and Loss of Disease Site Targeting Caused by Antibody Responses to PEGylated Liposomes

Judge, A. D., McClintock, K., Phelps, J. R., & MacLachlan, I. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.09.014 · Cited by 280 · see citing works

NOD-Like Receptors: Master Regulators of Inflammation and Cancer

Saxena, M., & Yeretssian, G. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00327 · Cited by 272 · see citing works

Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis

Robinson, E., MacDonald, K. D., Slaughter, K., McKinney, M., Patel, S., Sun, C., & Sahay, G. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.014 · Cited by 272 · see citing works

Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia

An, D., Schneller, J. L., Frassetto, A., Liang, S., Zhu, X., Park, J.-S., Theisen, M., Hong, S.-J., Zhou, J., Rajendran, R., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.081 · Cited by 263 · see citing works

Uridine Depletion and Chemical Modification Increase Cas9 mRNA Activity and Reduce Immunogenicity without HPLC Purification

Vaidyanathan, S., Azizian, K. T., Haque, A. K. M. A., Henderson, J. M., Hendel, A., Shore, S., Antony, J. S., Hogrefe, R. I., Kormann, M. S. D., Porteus, M. H., et al. (2018) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2018.06.010 · Cited by 262 · see citing works

Structural and functional insights into 5′-ppp RNA pattern recognition by the innate immune receptor RIG-I

Wang, Y., Ludwig, J., Schuberth, C., Goldeck, M., Schlee, M., Li, H., Juranek, S., Sheng, G., Micura, R., Tuschl, T., et al. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1863 · Cited by 256 · see citing works

Polysarcosine-functionalized lipid nanoparticles for therapeutic mRNA delivery

Nogueira, S. S., Schlegel, A., Maxeiner, K., Weber, B., Barz, M., Schroer, M. A., Blanchet, C. E., Svergun, D. I., Ramishetti, S., Peer, D., et al. (2020) · ACS Applied Nano Materials · doi:10.1021/acsanm.0c01834 · Cited by 252 · see citing works

PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake

Parhiz, H., Shuvaev, V. V., Pardi, N., Khoshnejad, M., Kiseleva, R. Y., Brenner, J. S., Uhler, T., Tuyishime, S., Mui, B. L., Tam, Y. K., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.015 · Cited by 233 · see citing works

PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: Faster PEG shedding attenuates anti-PEG IgM production

Suzuki, T., Suzuki, Y., Hihara, T., Kubara, K., Kondo, K., Hyodo, K., Yamazaki, K., Ishida, T., & Ishihara, H. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119792 · Cited by 227 · see citing works

Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo

Kuhn, A. N., Diken, M., Kreiter, S., Selmi, A., Kowalska, J., Jemielity, J., Darzynkiewicz, E., Huber, C., Türeci, Ö., & Sahin, U. (2010) · Gene Therapy · doi:10.1038/gt.2010.52 · Cited by 226 · see citing works

ADAR1: “Editor-in-Chief” of Cytoplasmic Innate Immunity

Lamers, M. M., van den Hoogen, B. G., & Haagmans, B. L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01763 · Cited by 224 · see citing works

Shielding of Lipid Nanoparticles for siRNA Delivery: Impact on Physicochemical Properties, Cytokine Induction, and Efficacy

Kumar, V., Qin, J., Jiang, Y., Duncan, R. G., Brigham, B., Fishman, S., Nair, J. K., Akinc, A., Barros, S. A., & Kasperkovitz, P. V. (2014) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2014.61 · Cited by 222 · see citing works

An origin of the immunogenicity of in vitro transcribed RNA

Mu, X., Greenwald, E., Ahmad, S., & Hur, S. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky177 · Cited by 218 · see citing works

Pseudo-anaphylaxis to Polyethylene Glycol (PEG)-Coated Liposomes: Roles of Anti-PEG IgM and Complement Activation in a Porcine Model of Human Infusion Reactions

Kozma, G. T., Mészáros, T., Vashegyi, I., Fülöp, T., Őrfi, E., Dézsi, L., Rosivall, L., Bavli, Y., Urbanics, R., Mollnes, T. E., et al. (2019) · ACS Nano · doi:10.1021/acsnano.9b03942 · Cited by 216 · see citing works

Translation of rabbit globin mRNA introduced by liposomes into mouse lymphocytes

DIMITRIADIS, G. J. (1978) · Nature · doi:10.1038/274923a0 · Cited by 212 · see citing works

A Combinatorial Library of Lipid Nanoparticles for RNA Delivery to Leukocytes

Ramishetti, S., Hazan‐Halevy, I., Palakuri, R., Chatterjee, S., Naidu, G. S., Dammes, N., Freilich, I., Shmuel, L. K., Danino, D., & Peer, D. (2020) · Advanced Materials · doi:10.1002/adma.201906128 · Cited by 212 · see citing works

Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles

Ramishetti, S., Kedmi, R., Goldsmith, M., Leonard, F., Sprague, A., Godin, B., Gozin, M., Cullis, P. R., Dykxhoorn, D. M., & Peer, D. (2015) · ACS Nano · doi:10.1021/acsnano.5b02796 · Cited by 210 · see citing works

Evaluation of Efficacy, Biodistribution, and Inflammation for a Potent siRNA Nanoparticle: Effect of Dexamethasone Co-treatment

Abrams, M. T., Koser, M. L., Seitzer, J., Williams, S. C., DiPietro, M. A., Wang, W., Shaw, A. W., Mao, X., Jadhav, V., Davide, J. P., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2009.208 · Cited by 209 · see citing works

Toxicity and immunogenicity concerns related to PEGylated-micelle carrier systems: a review

Shiraishi, K., & Yokoyama, M. (2019) · Science and Technology of Advanced Materials · doi:10.1080/14686996.2019.1590126 · Cited by 209 · see citing works

MAVS activates TBK1 and IKKε through TRAFs in NEMO dependent and independent manner

Fang, R., Jiang, Q., Zhou, X., Wang, C., Guan, Y., Tao, J., Xi, J., Feng, J., & Jiang, Z. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006720 · Cited by 208 · see citing works

In Vitro Transcription of Long RNA Containing Modified Nucleosides

Pardi, N., Muramatsu, H., Weissman, D., & Karikó, K. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-260-5_2 · Cited by 204 · see citing works

A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection

Kose, N., Fox, J. M., Sapparapu, G., Bombardi, R., Tennekoon, R. N., de Silva, A. D., Elbashir, S. M., Theisen, M. A., Humphris-Narayanan, E., Ciaramella, G., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aaw6647 · Cited by 202 · see citing works

Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers

Kremsner, P., Mann, P., Bosch, J., Fendel, R., Gabor, J. J., Kreidenweiss, A., Kroidl, A., Leroux-Roels, I., Leroux-Roels, G., Schindler, C., et al. (2020) · doi:10.1101/2020.11.09.20228551 · Cited by 199 · see citing works

Safety Evaluation of Lipid Nanoparticle–Formulated Modified mRNA in the Sprague-Dawley Rat and Cynomolgus Monkey

Sedic, M., Senn, J. J., Lynn, A., Laska, M., Smith, M., Platz, S. J., Bolen, J., Hoge, S., Bulychev, A., Jacquinet, E., et al. (2018) · Veterinary Pathology · doi:10.1177/0300985817738095 · Cited by 195 · see citing works

Selective targeting of nanomedicine to inflamed cerebral vasculature to enhance the blood–brain barrier

Marcos-Contreras, O. A., Greineder, C. F., Kiseleva, R. Y., Parhiz, H., Walsh, L. R., Zuluaga‐Ramirez, V., Myerson, J. W., Hood, E. D., Villa, C. H., Tombácz, I., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1912012117 · Cited by 187 · see citing works

Systemic messenger RNA as an etiological treatment for acute intermittent porphyria

Jiang, L., Berraondo, P., Jericó, D., Guey, L. T., Sampedro, A., Frassetto, A., Benenato, K. E., Burke, K., Santamaría, E., Alegre, M., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0199-z · Cited by 181 · see citing works

FLAM-seq: full-length mRNA sequencing reveals principles of poly(A) tail length control

Legnini, I., Alles, J., Karaiskos, N., Ayoub, S., Rajewsky, N., & Rajewsky, N. (2019) · Nature Methods · doi:10.1038/s41592-019-0503-y · Cited by 180 · see citing works

HIV Gag mRNA Transfection of Dendritic Cells (DC) Delivers Encoded Antigen to MHC Class I and II Molecules, Causes DC Maturation, and Induces a Potent Human In Vitro Primary Immune Response

Weissman, D., Ni, H., Scales, D. A., Dude, A., Capodici, J., McGibney, K., Abdool, A. J., Isaacs, S. N., Cannon, G., & Karikó, K. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.8.4710 · Cited by 178 · see citing works

Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates

Zhu, X., Yin, L., Theisen, M., Zhuo, J., Siddiqui, S., Levy, B., Presnyak, V., Frassetto, A., Milton, J., Salerno, T., et al. (2019) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2019.02.003 · Cited by 165 · see citing works

MicroRNAs Enable mRNA Therapeutics to Selectively Program Cancer Cells to Self-Destruct

Jain, R., Frederick, J. P., Huang, E. Y., Burke, K. E., Mauger, D. M., Andrianova, E. A., Farlow, S. J., Siddiqui, S., Pimentel, J., Cheung-Ong, K., et al. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0734 · Cited by 164 · see citing works

Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system

DeRosa, F., Guild, B., Karve, S., Smith, L., Love, K., Dorkin, J. R., Kauffman, K. J., Zhang, J., Yahalom, B., Anderson, D. G., et al. (2016) · Gene Therapy · doi:10.1038/gt.2016.46 · Cited by 159 · see citing works

Inosine induces context-dependent recoding and translational stalling

Licht, K., Hartl, M., Amman, F., Anrather, D., Janisiw, M. P., & Jantsch, M. F. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky1163 · Cited by 159 · see citing works

Ribonuclease L mediates the cell-lethal phenotype of double-stranded RNA editing enzyme ADAR1 deficiency in a human cell line

Li, Y., Banerjee, S., Goldstein, S. A., Dong, B., Gaughan, C., Rath, S. P., Donovan, J., Korennykh, A. V., Silverman, R. H., & Weiss, S. R. (2017) · eLife · doi:10.7554/elife.25687 · Cited by 156 · see citing works

Phosphorothioate cap analogs stabilize mRNA and increase translational efficiency in mammalian cells

Grudzien‐Nogalska, E., Jemielity, J., Kowalska, J., Darżynkiewicz, E., & Rhoads, R. E. (2007) · RNA · doi:10.1261/rna.701307 · Cited by 152 · see citing works

Lipid nanoparticle-targeted mRNA therapy as a treatment for the inherited metabolic liver disorder arginase deficiency

Truong, B., Allegri, G., Liu, X.-B., Burke, K. E., Zhu, X., Cederbaum, S. D., Häberle, J., Martini, P. G. V., & Lipshutz, G. S. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1906182116 · Cited by 151 · see citing works

Targeted mRNA Therapy for Ornithine Transcarbamylase Deficiency

Prieve, M. G., Harvie, P., Monahan, S. D., Roy, D., Li, A. G., Blevins, T. L., Paschal, A. E., Waldheim, M., Bell, E. C., Galperin, A., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.12.024 · Cited by 145 · see citing works

The identity and methylation status of the first transcribed nucleotide in eukaryotic mRNA 5’ cap modulates protein expression in living cells

Sikorski, P. J., Warminski, M., Kubacka, D., Ratajczak, T., Nowis, D., Kowalska, J., & Jemielity, J. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa032 · Cited by 142 · see citing works

Intrathecal delivery of frataxin mRNA encapsulated in lipid nanoparticles to dorsal root ganglia as a potential therapeutic for Friedreich’s ataxia

Nabhan, J. F., Wood, K. M., Rao, V. P., Morin, J., Bhamidipaty, S., LaBranche, T. P., Gooch, R. L., Bozal, F., Bulawa, C. E., & Guild, B. C. (2016) · Scientific Reports · doi:10.1038/srep20019 · Cited by 140 · see citing works

New insights into decapping enzymes and selective mRNA decay

Grudzien‐Nogalska, E., & Kiledjian, M. (2016) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1379 · Cited by 137 · see citing works

Synthesis of low immunogenicity RNA with high-temperature in vitro transcription

Wu, M. Z., Asahara, H., Tzertzinis, G., & Roy, B. (2020) · RNA · doi:10.1261/rna.073858.119 · Cited by 135 · see citing works

Structure of human IFIT1 with capped RNA reveals adaptable mRNA binding and mechanisms for sensing N1 and N2 ribose 2′-O methylations

Abbas, Y. M., Laudenbach, B. T., Martínez‐Montero, S., Cencic, R., Habjan, M., Pichlmair, A., Damha, M. J., Pelletier, J., & Nagar, B. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612444114 · Cited by 133 · see citing works

Synthesis and characterization of mRNA cap analogs containing phosphorothioate substitutions that bind tightly to eIF4E and are resistant to the decapping pyrophosphatase DcpS

Kowalska, J., Lewdorowicz, M., Zuberek, J., Grudzien‐Nogalska, E., Bojarska, E., Stȩpiński, J., Rhoads, R. E., Darżynkiewicz, E., Davis, R. E., & Jemielity, J. (2008) · RNA · doi:10.1261/rna.990208 · Cited by 130 · see citing works

Cationic lipid nanocarriers activate Toll-like receptor 2 and NLRP3 inflammasome pathways

Lonez, C., Bessodes, M., Scherman, D., Vandenbranden, M., Escriou, V., & Ruysschaert, J. (2013) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2013.12.003 · Cited by 129 · see citing works

IFIT1: A dual sensor and effector molecule that detects non-2′-O methylated viral RNA and inhibits its translation

Diamond, M. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.05.002 · Cited by 129 · see citing works

mRNA therapeutics deliver a hopeful message

Zhong, Z., Cafferty, S. M., Combes, F., Huysmans, H., Temmerman, J. D., Gitsels, A., Vanrompay, D. C. G., Catani, J. P., & Sanders, N. N. (2018) · Nano Today · doi:10.1016/j.nantod.2018.10.005 · Cited by 120 · see citing works

Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis

Butler, J. S., Chan, A., Costelha, S., Fishman, S., Willoughby, J. L. S., Borland, T. D., Milstein, S., Foster, D. J., Gonçalves, P., Chen, Q., et al. (2016) · Amyloid · doi:10.3109/13506129.2016.1160882 · Cited by 113 · see citing works

Evading innate immunity in nonviral mRNA delivery: don't shoot the messenger.

Devoldere, J., Dewitte, H., De Smedt, S. C., & Remaut, K. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2015.07.009 · Cited by 112 · see citing works

Optimization of mRNA untranslated regions for improved expression of therapeutic mRNA

Asrani, K. H., Farelli, J. D., Stahley, M. R., Miller, R. L., Cheng, C. J., Subramanian, R. R., & Brown, J. M. (2018) · RNA Biology · doi:10.1080/15476286.2018.1450054 · Cited by 111 · see citing works

Improved Efficacy in a Fabry Disease Model Using a Systemic mRNA Liver Depot System as Compared to Enzyme Replacement Therapy

DeRosa, F., Smith, L., Shen, Y., Huang, Y., Pan, J., Xie, H., Yahalom, B., & Heartlein, M. W. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.03.001 · Cited by 111 · see citing works

Ciphers and Executioners: How 3′-Untranslated Regions Determine the Fate of Messenger RNAs

Mayya, V. K., & Duchaîne, T. F. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00006 · Cited by 108 · see citing works

Influence of 5'-terminal cap structure on the initiation of translation of vaccinia virus mRNA.

Muthukrishnan, S., Moss, B. A., Cooper, J. A., et al. (1978) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)34923-2 · Cited by 106 · see citing works

Main trends of immune effects triggered by nanomedicines in preclinical studies

Halamoda‐Kenzaoui, B., & Bremer‐Hoffmann, S. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s168808 · Cited by 102 · see citing works

Overexpression of urokinase receptor in mammalian cells following administration of the in vitro transcribed encoding mRNA

Karikó, K., Kuo, A., & Barnathan, E. S. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300930 · Cited by 89 · see citing works

Long-term efficacy and safety of mRNA therapy in two murine models of methylmalonic acidemia

An, D., Frassetto, A., Jacquinet, E., Eybye, M., Milano, J., DeAntonis, C., Nguyen, V., Laureano, R., Milton, J., Sabnis, S., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.07.003 · Cited by 87 · see citing works

Cytokine-Release Syndrome: Overview and Nursing Implications

Breslin, S. (2007) · Clinical journal of oncology nursing · doi:10.1188/07.cjon.s1.37-42 · Cited by 85 · see citing works

The Importance of Poly(ethylene glycol) and Lipid Structure in Targeted Gene Delivery to Lymph Nodes by Lipid Nanoparticles

Zukancic, D., Suys, E. J. A., Pilkington, E. H., Algarni, A., Al-Wassiti, H. A., & Truong, N. P. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12111068 · Cited by 81 · see citing works

Nanoparticles containing constrained phospholipids deliver mRNA to liver immune cells in vivo without targeting ligands

Gan, Z., Lokugamage, M. P., Hatit, M. Z. C., Loughrey, D., Paunovska, K., Sato, M., Cristian, A., & Dahlman, J. E. (2020) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10161 · Cited by 75 · see citing works

G6PC mRNA therapy positively regulates fasting blood glucose and decreases liver abnormalities in a mouse model of glycogen storage disease 1a

Roseman, D. S., Khan, T., Rajas, F., Jun, L. S., Asrani, K. H., Isaacs, C., Farelli, J. D., & Subramanian, R. R. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.01.006 · Cited by 72 · see citing works

Variable Antibody-dependent Activation of Complement by Functionalized Phospholipid Nanoparticle Surfaces

Pham, C. T. N., Mitchell, L. M., Huang, J. L., Lubniewski, C. M., Schall, O. F., Killgore, J. K., Pan, D., Wickline, S. A., Lanza, G. M., & Hourcade, D. E. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.180760 · Cited by 71 · see citing works

mRNA Therapy Improves Metabolic and Behavioral Abnormalities in a Murine Model of Citrin Deficiency

Cao, J., An, D., Galduroz, M., Zhuo, J., Liang, S., Eybye, M., Frassetto, A., Kuroda, E., Funahashi, A., Santana, J., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.04.017 · Cited by 70 · see citing works

Dexamethasone prodrugs as potent suppressors of the immunostimulatory effects of lipid nanoparticle formulations of nucleic acids

Chen, S., Zaifman, J., Kulkarni, J. A., Zhigaltsev, I. V., Tam, Y. K., Ciufolini, M. A., Tam, Y. Y. C., & Cullis, P. R. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.07.026 · Cited by 68 · see citing works

SERPINA1 mRNA as a Treatment for Alpha-1 Antitrypsin Deficiency

Connolly, B., Isaacs, C., Cheng, L., Asrani, K. H., & Subramanian, R. R. (2018) · Journal of Nucleic Acids · doi:10.1155/2018/8247935 · Cited by 67 · see citing works

Immunostimulatory RNA oligonucleotides trigger an antigen-specific cytotoxic T-cell and IgG2a response

Bourquin, C., Schmidt, L., Hornung, V., Wurzenberger, C., Anz, D., Sandholzer, N., Schreiber, S. C., Voelkl, A., Hartmann, G., & Endres, S. (2006) · Blood · doi:10.1182/blood-2006-07-033258 · Cited by 64 · see citing works

Arginase I mRNA therapy – a novel approach to rescue arginase 1 enzyme deficiency

Asrani, K. H., Cheng, L., Cheng, C. J., & Subramanian, R. R. (2018) · RNA Biology · doi:10.1080/15476286.2018.1475178 · Cited by 58 · see citing works

Novel mRNA-Based Therapy Reduces Toxic Galactose Metabolites and Overcomes Galactose Sensitivity in a Mouse Model of Classic Galactosemia

Balakrishnan, B., An, D., Nguyen, V., DeAntonis, C. M., Martini, P. G. V., & Lai, K. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.09.018 · Cited by 57 · see citing works

The Ongoing Quest to Crack the Genetic Code for Protein Production

Nieuwkoop, T., Finger‐Bou, M., John van der, O. O. S. T., & Claassens, N. J. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.09.014 · Cited by 55 · see citing works

Innate immune response and programmed cell death following carrier-mediated delivery of unmodified mRNA to respiratory cells

Andries, O., Filette, M. D., Smedt, S. C. D., Demeester, J., Poucke, M. V., Peelman, L. J., & Sanders, N. N. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.01.033 · Cited by 54 · see citing works

Systemic modified messenger RNA for replacement therapy in alpha 1-antitrypsin deficiency

Karadagi, A., Cavedon, A. G., Zemack, H., Nowak, G., Eybye, M. E., Zhu, X., Guadagnin, E., White, R. A., Rice, L. M., Frassetto, A. L., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-64017-0 · Cited by 54 · see citing works

Quantitative Systems Pharmacology Model of hUGT1A1‐modRNA Encoding for the UGT1A1 Enzyme to Treat Crigler‐Najjar Syndrome Type 1

Apgar, J. F., Tang, J., Singh, P., Balasubramanian, N., Burke, J., Hodges, M. R., Lasaro, M. A., Lin, L., Miliard, B. L., Moore, K., et al. (2018) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12301 · Cited by 47 · see citing works

Critical residues involved in Toll-like receptor 4 activation by cationic lipid nanocarriers are not located at the lipopolysaccharide-binding interface

Lonez, C., Irvine, K. L., Pizzuto, M., Schmidt, B. I., Gay, N. J., Ruysschaert, J., Gangloff, M., & Bryant, C. E. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1915-1 · Cited by 46 · see citing works

mRNA as a Novel Treatment Strategy for Hereditary Spastic Paraplegia Type 5

Hauser, S., Poenisch, M., Schelling, Y., Höflinger, P., Schuster, S., Teegler, A., Betten, R., Gustafsson, J.-Å., Hübener‐Schmid, J., Schlake, T., et al. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.10.011 · Cited by 28 · see citing works

Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia

An, D., Schneller, J. L., Frassetto, A., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.08.049 · Cited by 25 · see citing works

mRNA treatment produces sustained expression of enzymatically active human ADAMTS13 in mice

Liu-Chen, S., Connolly, B., Cheng, L., Subramanian, R. R., & Han, Z. (2018) · Scientific Reports · doi:10.1038/s41598-018-26298-4 · Cited by 20 · see citing works

Lipid NanoparticlesFrom Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement

Tenchov, R., Bird, R., Curtze, A. E., & Zhou, Q. (2021) · ACS Nano · doi:10.1021/acsnano.1c04996 · Cited by 2,221 · see citing works

COVID-19 mRNA vaccines: Platforms and current developments

Szabó, G. T., Mahiny, A. J., & Vlatkovic, I. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.016 · Cited by 308 · see citing works

mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model

Sittplangkoon, C., Alameh, M.-G., Weissman, D., Lin, P. J. C., Tam, Y. K., Prompetchara, E., & Palaga, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.983000 · Cited by 79 · see citing works

Aggregation and Immunogenicity of Therapeutic Proteins

Filipe, V., Hawe, A., Schellekens, H., & Jiskoot, W. (2010) · doi:10.1002/9780470769829.ch10 · Cited by 39 · see citing works

Immunogenicity of Therapeutic Proteins

Swanson, S. J. (2010) · doi:10.1002/9780470595886.ch4 · Cited by 29 · see citing works

Immunogenicity

Galson, J. D., & O’Connor, D. (2015) · Encyclopedia of Life Sciences · doi:10.1002/9780470015902.a0000937

An overview of scientific and regulatory issues for the immunogenicity of biological products.

Chamberlain, P., & Mire‐Sluis, A. R. (2003) · PubMed · Cited by 31 · see citing works

[An experimental study of the immunogenicity of Pseudomonas aeruginosa vaccines].

Ns, A. (1976) · PubMed